{"id":1580,"date":"2010-07-13T15:28:48","date_gmt":"2010-07-13T19:28:48","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/avandia-day-1\/"},"modified":"2011-07-19T17:44:55","modified_gmt":"2011-07-19T21:44:55","slug":"avandia-day-1","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/07\/13\/avandia-day-1\/","title":{"rendered":"Avandia, Day 1\u00a0"},"content":{"rendered":"<p>A few hours before the start of the FDA&#8217;s advisory panel meeting on Avandia,<a href=\"http:\/\/go2.wordpress.com\/?id=725X1342&amp;site=cardiobrief.wordpress.com&amp;url=http%3A%2F%2Fwww.nytimes.com%2F2010%2F07%2F13%2Fhealth%2Fpolicy%2F13avandia.html%3F_r%3D1%26hp&amp;sref=http%3A%2F%2Fcardiobrief.org%2F\"> the <em>New York Times<\/em> published a story by Gardiner Harris<\/a> that said GlaxoSmithKline (GSK)&nbsp;began a study comparing the safety of rosiglitazone (Avandia) to pioglitazone (Actos) back in 1999 and spent the next 11 years keeping the study a secret.<\/p>\n<p>The Senate Finance Committee then released <a href=\"http:\/\/finance.senate.gov\/newsroom\/chairman\/download\/?id=a5c07780-6351-4905-8c63-52e4a7a7a66b\">a letter sent to FDA leaders and accompanying documents<\/a> detailing internal GSK discussions about the trial. GSK then issued its <a href=\"http:\/\/www.gsk.com\/media\/pressreleases\/2010\/2010_pressrelease_10075.htm\">response to the Senate letter and documents<\/a>.<\/p>\n<p>You can read detailed coverage of the FDA advisory panel by <a href=\"http:\/\/search.forbes.com\/search\/colArchiveSearch?author=matthew+and+herper&amp;aname=Matthew+Herper\">Matt Herper at Forbes.com<\/a> and by myself (Larry Husten) at <a href=\"http:\/\/cardiobrief.org\/\">CardioBrief.org<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A few hours before the start of the FDA&#8217;s advisory panel meeting on Avandia, the New York Times published a story by Gardiner Harris that said GlaxoSmithKline (GSK)&nbsp;began a study comparing the safety of rosiglitazone (Avandia) to pioglitazone (Actos) back in 1999 and spent the next 11 years keeping the study a secret. The Senate [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1580","post","type-post","status-publish","format-standard","hentry","category-general"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1580","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=1580"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1580\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=1580"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=1580"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=1580"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}